{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T23:16:03Z","timestamp":1785453363776,"version":"3.56.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"vor","delay-in-days":21,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"The Department of Science and Technology of Zhejiang Province","award":["2023R01012"],"award-info":[{"award-number":["2023R01012"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s00277-025-06399-7","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T01:32:02Z","timestamp":1747877522000},"page":"2717-2729","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Selective efficacy of venetoclax in unfit patients with acute myeloid leukemia with myelodysplasia-related gene mutations under low-intensity therapy"],"prefix":"10.1007","volume":"104","author":[{"given":"Jinya","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiupu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangwei","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijia","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiyan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiujin","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimin","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingsong","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donghua","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaofeng","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanmin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxian","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,22]]},"reference":[{"issue":"11","key":"6399_CR1","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP et al (2022) International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood 140(11):1200\u20131228","journal-title":"Blood"},{"issue":"1","key":"6399_CR2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41408-022-00774-7","volume":"13","author":"XC Tsai","year":"2023","unstructured":"Tsai XC, Sun KJ, Lo MY et al (2023) Poor prognostic implications of myelodysplasia-related mutations in both older and younger patients with de Novo AML. Blood Cancer J 13(1):4","journal-title":"Blood Cancer J"},{"issue":"3","key":"6399_CR3","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1111\/bjh.19614","volume":"205","author":"N Duployez","year":"2024","unstructured":"Duployez N, Preudhomme C (2024) Monitoring molecular changes in the management of myelodysplastic syndromes. Br J Haematol 205(3):772\u2013779","journal-title":"Br J Haematol"},{"issue":"12","key":"6399_CR4","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR et al (2022) Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140(12):1345\u20131377","journal-title":"Blood"},{"issue":"9","key":"6399_CR5","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1182\/bloodadvances.2019001349","volume":"4","author":"C Gardin","year":"2020","unstructured":"Gardin C, Pautas C, Fournier E et al (2020) Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results. Blood Adv 4(9):1942\u20131949","journal-title":"Blood Adv"},{"issue":"12","key":"6399_CR6","doi-asserted-by":"publisher","first-page":"e510","DOI":"10.1038\/bcj.2016.115","volume":"6","author":"A Nazha","year":"2016","unstructured":"Nazha A, Zarzour A, Al-Issa K et al (2016) The complexity of interpreting genomic data in patients with acute myeloid leukemia. Blood Cancer J 6(12):e510","journal-title":"Blood Cancer J"},{"issue":"21","key":"6399_CR7","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1182\/blood.2024025409","volume":"144","author":"H Dohner","year":"2024","unstructured":"Dohner H, DiNardo CD, Appelbaum FR et al (2024) Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations. Blood 144(21):2169\u20132173","journal-title":"Blood"},{"issue":"11","key":"6399_CR8","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1038\/s41375-023-01999-6","volume":"37","author":"E Jahn","year":"2023","unstructured":"Jahn E, Saadati M, Fenaux P et al (2023) Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients. Leukemia 37(11):2187\u20132196","journal-title":"Leukemia"},{"key":"6399_CR9","unstructured":"National Comprehensive Cancer Network (2024) NCCN clinical practice guideline in oncology: acute myeloid leukemia, version 3 [Internet]"},{"issue":"24","key":"6399_CR10","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1182\/blood.2020004856","volume":"135","author":"AH Wei","year":"2020","unstructured":"Wei AH, Montesinos P, Ivanov V et al (2020) Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood 135(24):2137\u20132145","journal-title":"Blood"},{"issue":"7","key":"6399_CR11","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V et al (2020) Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 383(7):617\u2013629","journal-title":"N Engl J Med"},{"issue":"25","key":"6399_CR12","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1200\/JCO.20.03736","volume":"39","author":"CD DiNardo","year":"2021","unstructured":"DiNardo CD, Lachowiez CA, Takahashi K et al (2021) Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia. J Clin Oncol 39(25):2768\u20132778","journal-title":"J Clin Oncol"},{"issue":"6","key":"6399_CR13","doi-asserted-by":"publisher","first-page":"e415","DOI":"10.1016\/S2352-3026(22)00106-5","volume":"9","author":"H Wang","year":"2022","unstructured":"Wang H, Mao L, Yang M et al (2022) Venetoclax plus 3\u2009+\u20097 Daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial. Lancet Haematol 9(6):e415\u2013e424","journal-title":"Lancet Haematol"},{"issue":"8","key":"6399_CR14","doi-asserted-by":"publisher","first-page":"e552","DOI":"10.1016\/S2352-3026(21)00192-7","volume":"8","author":"TM Kadia","year":"2021","unstructured":"Kadia TM, Reville PK, Borthakur G et al (2021) Venetoclax plus intensive chemotherapy with Cladribine, Idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial. Lancet Haematol 8(8):e552\u2013e561","journal-title":"Lancet Haematol"},{"issue":"15","key":"6399_CR15","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1182\/blood.2023020102","volume":"142","author":"J Xie","year":"2023","unstructured":"Xie J, Bao X, Xue SL et al (2023) Venetoclax with decitabine as frontline treatment in younger adults with newly diagnosed ELN adverse-risk AML. Blood 142(15):1323\u20131327","journal-title":"Blood"},{"issue":"19","key":"6399_CR16","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1182\/blood.2023020649","volume":"142","author":"J Senapati","year":"2023","unstructured":"Senapati J, Urrutia S, Loghavi S et al (2023) Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia. Blood 142(19):1647\u20131657","journal-title":"Blood"},{"issue":"6","key":"6399_CR17","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1182\/blood.2021013156","volume":"139","author":"CP Mill","year":"2022","unstructured":"Mill CP, Fiskus W, DiNardo CD et al (2022) Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2. Blood 139(6):907\u2013921","journal-title":"Blood"},{"issue":"12","key":"6399_CR18","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/ajh.26724","volume":"97","author":"S Venugopal","year":"2022","unstructured":"Venugopal S, DiNardo CD, Loghavi S et al (2022) Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemia. Am J Hematol 97(12):1560\u20131567","journal-title":"Am J Hematol"},{"key":"6399_CR19","doi-asserted-by":"publisher","first-page":"106735","DOI":"10.1016\/j.leukres.2021.106735","volume":"111","author":"S Chow","year":"2021","unstructured":"Chow S, Tang K, Al-Abri M et al (2021) RUNX1 mutations correlate with response to venetoclax combination therapies in relapsed\/refractory acute myeloid leukemia. Leuk Res 111:106735","journal-title":"Leuk Res"},{"issue":"4","key":"6399_CR20","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/s41375-024-02175-0","volume":"38","author":"S Shimony","year":"2024","unstructured":"Shimony S, Bewersdorf JP, Shallis RM et al (2024) Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML. Leukemia 38(4):762\u2013768","journal-title":"Leukemia"},{"issue":"7","key":"6399_CR21","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1038\/s41375-024-02230-w","volume":"38","author":"S Shimony","year":"2024","unstructured":"Shimony S, Garcia JS, Keating J et al (2024) Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients. Leukemia 38(7):1494\u20131500","journal-title":"Leukemia"},{"issue":"5","key":"6399_CR22","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1038\/leu.2012.303","volume":"27","author":"F Ferrara","year":"2013","unstructured":"Ferrara F, Barosi G, Venditti A et al (2013) Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy decision making. Leukemia 27(5):997\u2013999","journal-title":"Leukemia"},{"issue":"7","key":"6399_CR23","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/S1470-2045(13)70152-9","volume":"14","author":"J Jin","year":"2013","unstructured":"Jin J, Wang JX, Chen FF et al (2013) Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial. Lancet Oncol 14(7):599\u2013608","journal-title":"Lancet Oncol"},{"issue":"1","key":"6399_CR24","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3390\/cancers15010198","volume":"15","author":"Y Wang","year":"2022","unstructured":"Wang Y, Quesada AE, Zuo Z et al (2022) The impact of mutation of Myelodysplasia-Related genes in de Novo acute myeloid leukemia carrying NPM1 mutation. Cancers (Basel) 15(1):198","journal-title":"Cancers (Basel)"},{"issue":"1","key":"6399_CR25","doi-asserted-by":"publisher","first-page":"4622","DOI":"10.1038\/s41467-022-32103-8","volume":"13","author":"Y Tazi","year":"2022","unstructured":"Tazi Y, Arango-Ossa JE, Zhou Y et al (2022) Unified classification and risk-stratification in acute myeloid leukemia. Nat Commun 13(1):4622","journal-title":"Nat Commun"},{"issue":"8","key":"6399_CR26","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1182\/bloodadvances.2020004173","volume":"5","author":"CA Lachowiez","year":"2021","unstructured":"Lachowiez CA, Loghavi S, Furudate K et al (2021) Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax. Blood Adv 5(8):2173\u20132183","journal-title":"Blood Adv"},{"issue":"2","key":"6399_CR27","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.bbmt.2014.09.022","volume":"21","author":"RB Walter","year":"2015","unstructured":"Walter RB, Sandmaier BM, Storer BE et al (2015) Number of courses of induction therapy independently predicts outcome after allogeneic transplantation for acute myeloid leukemia in first morphological remission. Biol Blood Marrow Transpl 21(2):373\u2013378","journal-title":"Biol Blood Marrow Transpl"},{"issue":"5","key":"6399_CR28","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.amjms.2016.02.034","volume":"351","author":"S Wu","year":"2016","unstructured":"Wu S, Yang S, Zhu L et al (2016) Prognosis of patients with de Novo acute myeloid leukemia resistant to initial induction chemotherapy. Am J Med Sci 351(5):473\u2013479","journal-title":"Am J Med Sci"},{"issue":"2","key":"6399_CR29","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s00277-023-05096-7","volume":"102","author":"W Fu","year":"2023","unstructured":"Fu W, Hu Y, Lu G et al (2023) Re-induction therapy in patients with acute myeloid leukemia not in complete remission after the first course of treatment. Ann Hematol 102(2):329\u2013335","journal-title":"Ann Hematol"},{"issue":"8","key":"6399_CR30","doi-asserted-by":"publisher","first-page":"E299","DOI":"10.1002\/ajh.26600","volume":"97","author":"BA Jonas","year":"2022","unstructured":"Jonas BA, Wei AH, Recher C et al (2022) Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia. Am J Hematol 97(8):E299\u2013E303","journal-title":"Am J Hematol"},{"issue":"4","key":"6399_CR31","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1007\/s00277-024-05679-y","volume":"103","author":"Y Chen","year":"2024","unstructured":"Chen Y, Zheng J, Weng Y et al (2024) Myelodysplasia-related gene mutations are associated with favorable prognosis in patients with TP53-mutant acute myeloid leukemia. Ann Hematol 103(4):1211\u20131220","journal-title":"Ann Hematol"},{"key":"6399_CR32","volume-title":"Adverse prognostic impact of secondary-type mutations in ELN 2022 favorable risk acute myeloid leukemia. 29th annual European haematology meeting (EHA)","author":"D Kotsos","year":"2024","unstructured":"Kotsos D, Boertjes E, Gradowska P et al (2024) Adverse prognostic impact of secondary-type mutations in ELN 2022 favorable risk acute myeloid leukemia. 29th annual European haematology meeting (EHA). Madrid, Spain"},{"issue":"12","key":"6399_CR33","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1038\/s41409-022-01817-0","volume":"57","author":"GY Song","year":"2022","unstructured":"Song GY, Kim T, Ahn SY et al (2022) Allogeneic hematopoietic cell transplantation can overcome the adverse prognosis indicated by secondary-type mutations in de Novo acute myeloid leukemia. Bone Marrow Transpl 57(12):1810\u20131819","journal-title":"Bone Marrow Transpl"},{"issue":"6","key":"6399_CR34","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1182\/blood.2023022611","volume":"143","author":"VR Bhatt","year":"2024","unstructured":"Bhatt VR, Uy GL, Klepin HD (2024) Determining treatment tolerance and fitness for intensive chemotherapy in older adults with AML: a call to action. Blood 143(6):483\u2013487","journal-title":"Blood"},{"key":"6399_CR35","doi-asserted-by":"publisher","unstructured":"Abedin SM, Uy GL, Michaelis LC (2025) The fit older adult with acute myeloid leukemia: clinical challenges to providing evidence-based frontline treatment. Blood https:\/\/doi.org\/10.1182\/blood.2024026004","DOI":"10.1182\/blood.2024026004"},{"issue":"21","key":"6399_CR36","doi-asserted-by":"publisher","first-page":"4287","DOI":"10.1182\/blood-2012-12-471680","volume":"121","author":"HD Klepin","year":"2013","unstructured":"Klepin HD, Geiger AM, Tooze JA et al (2013) Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia. Blood 121(21):4287\u20134294","journal-title":"Blood"},{"issue":"11","key":"6399_CR37","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1182\/blood.2021013671","volume":"139","author":"GJ Min","year":"2022","unstructured":"Min GJ, Cho BS, Park SS et al (2022) Geriatric assessment predicts nonfatal toxicities and survival for intensively treated older adults with AML. Blood 139(11):1646\u20131658","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06399-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06399-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06399-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T06:37:45Z","timestamp":1749105465000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06399-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["6399"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06399-7","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"15 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Ethics Review Committee of the First Affiliated Hospital of Zhejiang University School of Medicine (approval number 20240635A) and was conducted according to the principles of the Helsinki Declaration. Informed consent was obtained from all individual participants included in the study. The authors declare no known no potential conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}